Summary of Research: Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease - The FIDELITY Pooled Analysis

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Summary of Research : Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease - The FIDELITY Pooled Analysis. / Humle, Karin; Klanger, Boris; Kolkhof, Peter; Rosas, Sylvia E.; Rossing, Peter; Wright, Eugene; Jefferson, Nichole.

I: Diabetes Therapy, Bind 15, Nr. 9, 2024, s. 1861-1864.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Humle, K, Klanger, B, Kolkhof, P, Rosas, SE, Rossing, P, Wright, E & Jefferson, N 2024, 'Summary of Research: Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease - The FIDELITY Pooled Analysis', Diabetes Therapy, bind 15, nr. 9, s. 1861-1864. https://doi.org/10.1007/s13300-024-01591-w

APA

Humle, K., Klanger, B., Kolkhof, P., Rosas, S. E., Rossing, P., Wright, E., & Jefferson, N. (2024). Summary of Research: Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease - The FIDELITY Pooled Analysis. Diabetes Therapy, 15(9), 1861-1864. https://doi.org/10.1007/s13300-024-01591-w

Vancouver

Humle K, Klanger B, Kolkhof P, Rosas SE, Rossing P, Wright E o.a. Summary of Research: Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease - The FIDELITY Pooled Analysis. Diabetes Therapy. 2024;15(9):1861-1864. https://doi.org/10.1007/s13300-024-01591-w

Author

Humle, Karin ; Klanger, Boris ; Kolkhof, Peter ; Rosas, Sylvia E. ; Rossing, Peter ; Wright, Eugene ; Jefferson, Nichole. / Summary of Research : Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease - The FIDELITY Pooled Analysis. I: Diabetes Therapy. 2024 ; Bind 15, Nr. 9. s. 1861-1864.

Bibtex

@article{0dd9b18db2ba47c7a7b93ad25b574619,
title = "Summary of Research: Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease - The FIDELITY Pooled Analysis",
abstract = "People living with type 2 diabetes (T2D) and chronic kidney disease (CKD) are at risk of CKD progression and kidney failure. This is a summary of the FIDELITY pooled analysis where two clinical trials (FIDELIO-DKD and FIGARO-DKD) were performed to investigate the safety and efficacy of finerenone in people with T2D and CKD. The data from these two studies were combined and analyzed and it was found that those who took finerenone on top of standard-of-care medicine had a 14% reduced risk of having a cardiovascular event and 23% reduced risk of having a kidney event versus those who took placebo. Those who took finerenone were also more likely to have high blood potassium, but this was mostly manageable. A graphical abstract and translations of all content (Chinese, Japanese, German, Spanish, Brazilian-Portuguese, French) are available for this article.",
keywords = "Cardiovascular disease, Chronic kidney disease, Finerenone, Type 2 diabetes",
author = "Karin Humle and Boris Klanger and Peter Kolkhof and Rosas, {Sylvia E.} and Peter Rossing and Eugene Wright and Nichole Jefferson",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",
year = "2024",
doi = "10.1007/s13300-024-01591-w",
language = "English",
volume = "15",
pages = "1861--1864",
journal = "Diabetes Therapy",
issn = "1869-6953",
publisher = "Springer",
number = "9",

}

RIS

TY - JOUR

T1 - Summary of Research

T2 - Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease - The FIDELITY Pooled Analysis

AU - Humle, Karin

AU - Klanger, Boris

AU - Kolkhof, Peter

AU - Rosas, Sylvia E.

AU - Rossing, Peter

AU - Wright, Eugene

AU - Jefferson, Nichole

N1 - Publisher Copyright: © The Author(s) 2024.

PY - 2024

Y1 - 2024

N2 - People living with type 2 diabetes (T2D) and chronic kidney disease (CKD) are at risk of CKD progression and kidney failure. This is a summary of the FIDELITY pooled analysis where two clinical trials (FIDELIO-DKD and FIGARO-DKD) were performed to investigate the safety and efficacy of finerenone in people with T2D and CKD. The data from these two studies were combined and analyzed and it was found that those who took finerenone on top of standard-of-care medicine had a 14% reduced risk of having a cardiovascular event and 23% reduced risk of having a kidney event versus those who took placebo. Those who took finerenone were also more likely to have high blood potassium, but this was mostly manageable. A graphical abstract and translations of all content (Chinese, Japanese, German, Spanish, Brazilian-Portuguese, French) are available for this article.

AB - People living with type 2 diabetes (T2D) and chronic kidney disease (CKD) are at risk of CKD progression and kidney failure. This is a summary of the FIDELITY pooled analysis where two clinical trials (FIDELIO-DKD and FIGARO-DKD) were performed to investigate the safety and efficacy of finerenone in people with T2D and CKD. The data from these two studies were combined and analyzed and it was found that those who took finerenone on top of standard-of-care medicine had a 14% reduced risk of having a cardiovascular event and 23% reduced risk of having a kidney event versus those who took placebo. Those who took finerenone were also more likely to have high blood potassium, but this was mostly manageable. A graphical abstract and translations of all content (Chinese, Japanese, German, Spanish, Brazilian-Portuguese, French) are available for this article.

KW - Cardiovascular disease

KW - Chronic kidney disease

KW - Finerenone

KW - Type 2 diabetes

U2 - 10.1007/s13300-024-01591-w

DO - 10.1007/s13300-024-01591-w

M3 - Journal article

C2 - 39028367

AN - SCOPUS:85199098162

VL - 15

SP - 1861

EP - 1864

JO - Diabetes Therapy

JF - Diabetes Therapy

SN - 1869-6953

IS - 9

ER -

ID: 400740956